Results 171 to 180 of about 333,009 (323)
Chinese Toxic Language Mitigation via Sentiment Polarity Consistent Rewrites [PDF]
Xintong Wang +5 more
openalex +1 more source
Graph rewrites, from graphic lambda calculus, to chemlambda, to directed\n interaction combinators [PDF]
Marius Buliga
openalex +1 more source
ABSTRACT Background Apolipoprotein ε4 (APOE ε4) is a potent genetic risk factor for Alzheimer's disease (AD). However, its role in cerebral small vessel disease (CSVD) remains unclear. Given the clinical and pathological similarities between CSVD and AD, this study aimed to investigate the associations of APOE ε4 gene dosage with cognitive function and
Tingru Jin +6 more
wiley +1 more source
Coherence in popularized medico-pharmaceutical reports: The case of EPAR summaries for the public
The present article investigates a particular lay-oriented medico-pharmaceutical genre, viz. the European Public Assessment Report – summary for the public, which is a summarized version of a much longer specialized report published by the European ...
Aage Hill-Madsen
doaj
Tunable Optical Metamaterial Enables Steganography, Rewriting, and Multilevel Information Storage. [PDF]
Zheng J +9 more
europepmc +1 more source
Ontological Queries: Rewriting and Optimization (Extended Version) [PDF]
Georg Gottlob +2 more
openalex +1 more source
RAB39B Related Parkinsonism in an Italian Family: A Unique Use of Advanced Therapies
ABSTRACT Parkinson's disease (PD) is a neurodegenerative disorder that may sometimes be caused by deleterious genetic variants. Among them, RAB39B polymorphisms are known as rare causes of early‐onset PD associated with intellectual disability (Waisman's syndrome).
Caterina Del Regno +13 more
wiley +1 more source
Laser-Induced Covalent Defunctionalization of Graphene - Precise Patterning and Site-Selective Removal of Functional Groups. [PDF]
Nagel T, Gerein K, Hauke F, Hirsch A.
europepmc +1 more source
ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu +9 more
wiley +1 more source

